CommsRx · Independent commentary

Ally’s Read.

Weekly, one therapy area at a time: what happened, what is scheduled, and what the AI answer engines say about it, with the public sources each piece rests on. From CommsRx.

Edition 1 · October 20, 2026

Same Drug, Different Story: How AI Tailors Lung Cancer Advice to Who You Say You Are

On November 14, 2026, the FDA is due to decide on ivonescimab, a lung cancer drug approved in China, given with chemotherapy for EGFR-mutated lung cancer that grew after targeted treatment. Four AI assistants got its approval status right in all 75 answers. But a caregiver heard about side effects in 11 of 13 answers, and an oncologist heard the benefit in 11 of 12. Only 10 of 50 answers to four askers gave both.

Follow the therapy areas.

Immunology Alzheimer's and neuroscience Obesity and cardiometabolic Oncology Rare disease and gene therapy Vaccines

What this is.

Each piece lists the public sources it rests on, and the date beside a source is when an editor last checked it.

How the Read is made →